Teamwork Financial Advisors LLC Has $317,000 Stake in Abbott Laboratories $ABT

Teamwork Financial Advisors LLC lowered its stake in Abbott Laboratories (NYSE:ABT) by 85.6% in the fourth quarter, Holdings Channel reports. The fund owned 2,532 shares of the healthcare product maker’s stock after selling 15,017 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Abbott Laboratories were worth $317,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the third quarter worth $31,000. Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories during the second quarter worth $32,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the third quarter worth $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories in the 3rd quarter valued at $38,000. 75.18% of the stock is owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company’s stock, valued at $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last ninety days. Insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of a number of research reports. Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Raymond James Financial dropped their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Sanford C. Bernstein reduced their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group dropped their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Finally, Barclays cut their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Trading Down 1.5%

ABT opened at $105.58 on Monday. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06. The company has a fifty day moving average of $112.75 and a 200-day moving average of $122.97. The stock has a market cap of $183.88 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 1.68 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.